Table 3.
Hazard ratio of MACE by 10-year ASCVD risk categories.
| Among PS matched cohort | Low | Borderline | Intermediate | High | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| (n = 44,616) | HR | 95% CI | HR | 95% CI | HR | 95% CI | HR | 95% CI | ||||
| MACE | 1.80 | 1.29 | 2.52 | 1.15 | 0.86 | 1.54 | 0.94 | 0.85 | 1.03 | 0.83 | 0.71 | 0.96 |
| MI | 4.14 | 1.98 | 8.67 | 1.08 | 0.63 | 1.86 | 1.29 | 1.02 | 1.62 | 1.10 | 0.77 | 1.56 |
| Ischemic stroke | 1.41 | 0.95 | 2.09 | 1.26 | 0.90 | 1.78 | 0.88 | 0.79 | 0.98 | 0.82 | 0.70 | 0.97 |
| CVD death | 1.59 | 0.36 | 7.10 | 1.17 | 0.20 | 7.03 | 1.09 | 0.71 | 1.68 | 0.82 | 0.47 | 1.40 |
Hazard ratio (HR) was obtained with reference to the statin non-user group. CVD, cardiovascular disease; ASCVD, atherosclerotic CVD; MACE, major adverse cardiovascular events; MI, myocardial infarction; CI, confidence interval.